Gland Pharma and Neuland Laboratories enter into a long-term contract manufacturing partnership focused on sterile active pharmaceutical ingredient (API) production, according to reports from Times of India and BusinessLine. The collaboration centres on planning, building and operating a sterile API manufacturing facility designed to meet regulatory and quality standards. The outlets state that the facility will be operated under current Good Manufacturing Practice (cGMP) requirements and aligned with US FDA and EU standards.
The partnership leverages Gland Pharma’s experience in aseptic manufacturing. BusinessLine adds that the company’s “proven aseptic manufacturing expertise” is intended to support the facility’s production capabilities. Times of India and BusinessLine both describe the relationship as a CDMO-style arrangement, with Gland Pharma’s role linked to sterile/API know-how and Neuland contributing through its manufacturing and partnership capabilities.
Both reports frame the agreement as a long-term manufacturing collaboration for sterile APIs, with the facility’s construction and operations intended to satisfy US and European compliance expectations.
